We build on our deep scientific knowledge and innovation and offer preestablished assays, adaptable platforms, and bespoke services to understand function, validate mechanisms, and support clinical campaigns. Our experience spans:

• Recombinant Proteins
• Monoclonal Antibodies (mAbs)
• Antibody-Drug Conjugates (ADCs)
• Immune Cell Engagers
• Multi-specific antibodies
• Peptides
• Cytokine-fusions
• Nanoparticles

We provide integrated services to support large molecule development through discovery, preclinical, and clinical manufacture phases. Combining deep understanding, state-of-the-art equipment, and scientific expertise, we are leaders in:

• Disease Modelling and Target Validation
• In Vitro Pharmacology
• Immunotoxicology
• Product Characterisation
• Cell Engineering
• Biosimilar Characterisation

Our immune cell assays evaluate therapeutic interactions with targets and the tumour microenvironment, generating high-content data. Our patented IndEx-2 system uniquely assesses antigen density impact on therapeutic efficacy and safety.

Our bioanalytical services offer assays for binding and biological activity, including target binding affinity and multispecific format assessments. We excel in creating potency methods and bespoke cell lines for product release.

For antibodies, we assess Fcγ and C1q binding and effector function, using engineered target cells and screened primary cell donors. Our expertise in in vitro pharmacology for immune cell engagers ensures comprehensive evaluation and validation of therapeutic candidates.

Partner with us to navigate the complexities of large molecule development and achieve your therapeutic goals.